FDA announces labeling changes to opioid pain medications
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain the risks associated with long-term use. The updates include presenting clearer risk information, stronger dosing warnings, clarified language on use limits, treatment guidance and more. Manufacturers were given 30 days to submit their labeling updates to the FDA for review.
Related News Articles
Perspective
More than 48 million Americans — 16.8% of the 12-and-older population — have a substance use disorder (SUD), according to the 2025 National Survey on Drug Use…
Headline
HHS awards $1.5 billion in opioid response grants to states, tribal communities The Department of Health and Human Services announced yesterday that it…
Headline
The Senate Sept. 18 passed the AHA-supported SUPPORT Act (H.R. 2483) by a voice vote, advancing the bill to President Trump to sign into law. The bill…
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The Centers for Disease Control and Prevention Aug. 5 announced a new campaign educating youth ages 12-17 on substance use, mental health and how they are…